Peripheral T-Cell Lymphoma, Not Otherwise Specified Clinical Trials

9 recruitingLast updated: June 18, 2026

There are 9 actively recruiting peripheral t-cell lymphoma, not otherwise specified clinical trials across 3 countries. Studies span Phase 1, Phase 2, Phase 3. Top locations include Duarte, California, United States, Rochester, Minnesota, United States, New York, New York, United States. Updated daily from ClinicalTrials.gov.


Peripheral T-Cell Lymphoma, Not Otherwise Specified Trials at a Glance

9 actively recruiting trials for peripheral t-cell lymphoma, not otherwise specified are listed on ClinicalTrialsFinder across 6 cities in 3 countries. The largest study group is Phase 1 with 5 trials, with the heaviest enrollment activity in Duarte, Rochester, and New York. Lead sponsors running peripheral t-cell lymphoma, not otherwise specified studies include City of Hope Medical Center, Mayo Clinic, and Corvus Pharmaceuticals, Inc..

Browse peripheral t-cell lymphoma, not otherwise specified trials by phase

Treatments under study

About Peripheral T-Cell Lymphoma, Not Otherwise Specified Clinical Trials

Looking for clinical trials for Peripheral T-Cell Lymphoma, Not Otherwise Specified? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Peripheral T-Cell Lymphoma, Not Otherwise Specified trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Peripheral T-Cell Lymphoma, Not Otherwise Specified clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 19 of 9 trials

Recruiting
Phase 1Phase 2

Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma

Recurrent Mycosis FungoidesRefractory Mycosis FungoidesSezary Syndrome+5 more
City of Hope Medical Center78 enrolled4 locationsNCT03011814
Recruiting
Phase 1

Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma

Peripheral T-Cell Lymphoma, Not Otherwise SpecifiedPeripheral T Cell LymphomaRelapsed Peripheral T-Cell Lymphoma+4 more
Mayo Clinic21 enrolled2 locationsNCT06508463
Recruiting
Phase 1

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

Myelodysplastic SyndromeB-cell Non Hodgkin LymphomaRefractory Acute Myeloid Leukemia+16 more
Mayo Clinic99 enrolled2 locationsNCT03017820
Recruiting
Phase 1

Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas

Peripheral T-Cell Lymphoma, Not Otherwise SpecifiedMature T-Cell and NK-Cell Non-Hodgkin LymphomaFollicular Helper T-Cell Lymphoma+3 more
City of Hope Medical Center20 enrolled1 locationNCT07278856
Recruiting
Phase 2

Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas

Peripheral T-Cell Lymphoma, Not Otherwise SpecifiedFollicular Helper T-Cell Lymphoma
City of Hope Medical Center25 enrolled1 locationNCT07293403
Recruiting

A Registry for People With T-cell Lymphoma

T-cell LymphomaNK-Cell LymphomaT-cell Prolymphocytic Leukemia+27 more
Memorial Sloan Kettering Cancer Center1,000 enrolled26 locationsNCT05978141
Recruiting
Phase 3

Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

Peripheral T-Cell Lymphoma, Not Otherwise SpecifiedAnaplastic Large Cell Lymphoma, ALK-negativeFollicular Helper T-Cell Lymphoma+1 more
Eastern Cooperative Oncology Group294 enrolled158 locationsNCT06724237
Recruiting
Phase 3

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

Lymphoma, T-CellPeripheral T-Cell Lymphoma, Not Otherwise SpecifiedAngioimmunoblastic T-cell Lymphoma+4 more
Corvus Pharmaceuticals, Inc.150 enrolled34 locationsNCT06561048
Recruiting
Phase 1

Q702 for the Treatment of Patients With Hematologic Malignancies

Hematopoietic and Lymphatic System NeoplasmHistiocytic SarcomaMalignant Histiocytosis+34 more
Mayo Clinic46 enrolled2 locationsNCT06712810